Steve Jobs predicted, “The biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.”
And we’re starting to see that happen.
As I told you on Saturday, some experts predict that by 2040, generative AI could result in $1 trillion in value for healthcare.
Nvidia CEO Jensen Huang said it will be “the next amazing revolution [and] one of the biggest ever.”
Those are powerful words coming from someone like him.
But let me be clear… This isn’t just biotech 2.0.
This revolution is so huge and so radical that scientists have come up with an entirely new word for it…
TechBio.
It’s more than just a buzzword. It’s a true paradigm shift.
Biotech typically starts with the biological elements – living organisms, biological molecules, genetic material, etc. – and then applies data analysis, engineering principles and technology to manipulate or harness those biological components for desired products or outcomes.
TechBio, on the other hand, often begins from an engineering, data science or technological standpoint. It leverages tools, devices, computational power and technologies first and then applies or integrates them with biological systems to study, measure or interface with those living systems.
TechBio signifies a uniquely sophisticated method of drug development.
And it can’t be done without AI.
Thanks to these innovations, we’re starting to see how AI can accelerate the whole process of discovery and testing new compounds. It’s taking a fraction of the time… in some cases making the process as much as 15 times faster.
A study by Carnegie Mellon suggests AI could ultimately cut costs by as much as 70%.
So AI is just the thing that will ignite a massive rally in these stocks. And soon.
But that’s not all…
A Perfect Storm Is Brewing
The cherry on top?
Morgan Stanley analysts point out that a Fed rate cut will also fuel these stocks, writing, “In our view, there have been green shoots pointing to the beginnings of a rally in the biotech industry.”
All year, I’ve been saying rate cuts wouldn’t come as quickly as most people expected, and I’ve been proven right. But one is coming eventually.
And when that happens, look for this corner of the market to really take off.
Why?
Low rates provide a favorable financing environment and increase the valuations of biotech firms’ pipelines, driving outperformance in the sector.
Add it all up, and there’s NEVER been a better time to jump into this market.
The post “TechBio”: A New Era of Innovation appeared first on Wealthy Retirement.
